Medicus Pharma Ltd.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $7.7M | $3.5M | $193,578 | — |
| Operating expenses | $34.4M | $11.2M | $4.7M | — |
| Operating income | -$34.4M | -$11.2M | -$4.7M | — |
| Income tax expense | $0 | $0 | $0 | — |
| Net income | -$47.3M | -$11.2M | -$5.3M | — |
| Balance Sheet | ||||
| Cash and equivalents | $8.7M | $4.2M | $1.7M | — |
| Current assets | $9.9M | $5.4M | $1.9M | — |
| Total assets | $10.1M | $5.6M | $1.9M | — |
| Current liabilities | $9.9M | $2.3M | $781,609 | — |
| Total liabilities | $10.0M | $2.5M | $781,609 | — |
| Stockholders' equity | -$67,554 | $3.1M | $1.1M | -$12.2M |
| Cash Flow Statement | ||||
| Cash from operations | -$22.8M | -$10.2M | -$4.2M | — |
| Stock-based compensation | $1.5M | $713,119 | $98,585 | — |
Shares outstanding 56.7M · Free float 86.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.